19.05.2025 • Bookbooks

Pharma and Profits

Pharma and Profits; Balancing Innovation, Medicine, and Drug Prices
1. Edition September 2022, Wiley & Sons Ltd ; 112 Pages, Softcover, €25,60
ISBN: 978-1-119-88133-9

Author: LaMattina, John L.

Photo
© Wiley

Balancing Innovation, Medicine, and Drug Prices

High-level commentary on various facets of the pharmaceutical industry from a key leader in the field

Pharma and Profits clearly explains the value that the pharmaceutical industry offers to society which is often underreported against the more negative topic of high drug prices. It also offers an overview for drug discovery and development professionals, highlighting the challenges that such drug hunters should be aware of when developing new drugs. Case studies to illustrate topics like hepatitis C, mRNA vaccines, insulin, and price controls are included to aid in seamless reader comprehension.

Written by John LaMattina, former president of Pfizer Global Research and Development and well-known speaker and writer for the pharma industry, sample topics covered and questions explored within the work include:

  • Fiscal consequences of curing hepatitis C
  • mRNA vaccines and the race for a cure
  • Why the government does not deserve a piece of Biopharma's profits
  • Paying for drugs whose ultimate value is unknown
  • The impact of reduced revenues on R&D

This book is a must-read for biopharmaceutical professionals and executives who wish to gain high-level insight into key challenges that must be first understood, then overcome, within the pharmaceutical industry.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read